Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... [Yahoo! Finance]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Yahoo! Finance
Altimmune Inc ( NASDAQ:ALT ) has fully enrolled its Phase 2B impact trial for PTI IN MS, with top-line efficacy data expected in Q2 2025. The company achieved alignment with the FDA on a comprehensive Phase 3 registration program for its obesity program, indicating a clear regulatory path forward. Altimmune Inc ( NASDAQ:ALT ) plans to expand its R&D investments into three additional indications, leveraging the enhanced glucagon activity of its product. The company has a strong cash position, with $139.4 million in cash, cash equivalents, and short-term investments, projected to fund operations into the first half of 2026. Altimmune Inc ( NASDAQ:ALT ) has received positive feedback from the FDA regarding the safety profile of its product, with no safety signals identified in its trials. The company's net loss for Q3 2024 was $22.8 million, an increase from the $20.7 million loss in the same period of 2023. Research and development expenses increased to $19.8 million in Q3
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Do Redditors Think That Altimmune Inc. (ALT) Has a Big Upside Potential? [Yahoo! Finance]Yahoo! Finance
- Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 [Yahoo! Finance]Yahoo! Finance
- Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024GlobeNewswire
- Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Altimmune, Inc. (NASDAQ: ALT) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $26.00 price target on the stock.MarketBeat
ALT
Earnings
- 11/12/24 - Beat
ALT
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 4
- 11/12/24 - Form 3
- ALT's page on the SEC website